A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT07690319
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.
Key Dates
- First listed
- Jul 8, 2026
- Start date
- Oct 15, 2026
- Status verified
- Jun 2026
- Primary completion
- Mar 15, 2027
- Completion
- Mar 15, 2027
Study Design
- Enrollment
- 186 participants (estimated)
Arms
- Arm: Early Treatment GroupAdult patients with moderate to severe HS, having up to 1 active tunnel (draining or non-draining) or up to 4 inflammatory lesions (abscess/nodules) at date of first secukinumab administration for HS treatment.
- Arm: Late Treatment GroupAdult patients with moderate to severe HS, having \>1 active tunnel or \>4 inflammatory lesions, at date of first secukinumab administration for HS treatment.
Primary Outcome Measure
Proportion of Patients Achieving 55% Reduction From Baseline in International Hidradenitis Suppurativa Severity Scoring System (IHS4-55) at 6 and 12 Months [ Time Frame: 6 and 12 months ]
Central Contacts
- Novartis Pharmaceuticals+41613241111
- Novartis Pharmaceuticals
Find similar trials
Related Studies
- The Ohio State University Dermatology BiorepositoryRecruiting · Ohio State University · Columbus, Ohio
- Clinical and Biological Characteristics of Hidradenitis SuppurativaRecruiting · University of California, San Francisco · San Francisco, California
- Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen RepositoryRecruiting · University of California, San Francisco · San Francisco, California
- Battlefield Acupuncture for Pain in Hidradenitis SuppurativaRecruiting · Wayne State University · Dearborn, Michigan